When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment.
about
Tips for learners of evidence-based medicine: 1. Relative risk reduction, absolute risk reduction and number needed to treatClinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studiesEpistemologic inquiries in evidence-based medicine.A generalised model for individualising a treatment recommendation based on group-level evidence from randomised clinical trialsPatient's preferences for health scenarios associated with hepatitis C and its treatmentQuantifying the impact of community quarantine on SARS transmission in Ontario: estimation of secondary case count difference and number needed to quarantineVariation among institutional review boards in evaluating the design of a multicenter randomized trialGuidelines for the management of bacterial and fungal infections during chemotherapy for pediatric acute leukemia or solid tumors: what is available in 2010?Selecting patients for randomized trials: a systematic approach based on risk group.Risk threshold for starting low dose aspirin in pregnancy to prevent preeclampsia: an opportunity at a low cost.A new paradigm for the prediction of antidepressant treatment responseThe application of number needed to treat (NNT) to clinical problems in radiotherapy.Targeting Uric Acid and the Inhibition of Progression to End-Stage Renal Disease--A Propensity Score Analysis.How should we describe the benefits of palliative radiotherapy?How do researchers determine the difference to be detected in superiority trials? Results of a survey from a panel of researchers.Approaching clinical problems in prostate cancer radiotherapy using the number needed to treat (NNT) technique.Planning clinically relevant biomarker validation studies using the "number needed to treat" concept.Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach.Use of clinical neurophysiology for the selection of medication in the treatment of major depressive disorder: the state of the evidence.Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconvertersPublic-private partnerships improve health outcomes in individuals with early stage Alzheimer's disease.When is rational to order a diagnostic test, or prescribe treatment: the threshold model as an explanation of practice variation.No need for rescue medication (NNR) as an easily interpretable efficacy outcome measure in analgesic trials: validation in an individual-patient meta-analysis of dental pain placebo-controlled trials of naproxen.Targeting chemotherapy to advanced bladder cancer patients most likely to benefit.The role of prophylaxis of bacterial infections in children with acute leukemia/non-hodgkin lymphoma.Medical decision making and the importance of baseline riskThe international intravitreal bevacizumab safety survey.Expected utility versus expected regret theory versions of decision curve analysis do generate different results when treatment effects are taken into account.Operational research on perinatal epidemiology, care and outcomes.Are We Ready for Patient-Based Effect Sizes in Clinical-Trials Research?
P2860
Q24564452-0604399E-BB88-45FD-BE0B-DD61A53FAAD1Q26752308-89FECE2E-4FB1-4932-B075-AE0C6AB8A77BQ30375899-95BA3BCB-5C1C-47FA-A4BB-1F352C7119F9Q30543580-B80442C2-C84B-423E-81BC-D901FDBCCD8EQ33573128-7D852EF1-5E1F-4679-BC81-F3E474257403Q33598235-7AC43F20-D6E5-44DF-AA85-6302A059910EQ34076286-80E0DCAC-E2AB-4CE6-9AF7-B9539AC2EB84Q35010346-71B15B6D-1DF1-4BB1-8A67-5FE164FCA1ACQ35090732-95808D2D-3FAB-48E6-BC3D-A0664D5ED003Q35196095-CEE43941-F8F5-416F-BB4B-0451DF63C973Q35237120-FD7E7DEA-7F47-45E3-B0AD-AFEA22F4BDE4Q35806747-5086FFF3-0924-4AAD-BFE4-DEA35C9A5CF6Q35877440-D812B8E7-5306-4472-8635-8F9EC1976F8DQ36089090-059EE45E-685B-4006-B1BD-D2D1B1DB20BAQ36090159-D59E2D10-F852-453E-853A-9FED9599E7D3Q36523509-EEE64EF8-FC18-4AFC-B6E4-FA94067B390DQ36871429-5611B60A-FADF-4A32-BA2F-25A6A8B20A5FQ37445971-119AB934-93A2-4E9D-9947-63DE30BCE17DQ37522358-A44A7F44-14E2-4A54-B00A-419B1E32EFCFQ37651390-75E156A5-6B40-422B-93FC-2A5CA02539A9Q37702268-7F43D6E7-DD52-4082-8600-9413A9578F71Q38353140-74569442-7E5D-4F85-856C-B88DDDA54C59Q39237892-23A045B6-EA46-4D2B-BB5F-C8A1D52A829AQ39901909-054521D1-696D-4B55-B5C0-7663EFA743A6Q41548221-4EFEA40A-4C1E-4F56-BCA3-62BC24ABC896Q41845051-E31B5E98-1BBC-4632-B73A-BB84ADDA768CQ42841120-2FBD166B-E0BB-4950-9BED-7F66E2C2A4F7Q47362526-E136FAA8-C7BB-4DA9-9B40-3CFA5D30DA17Q52013936-B373EA51-9DED-42C3-BF64-3170E6E19FACQ58003995-F082F0D8-718C-482E-8ABE-34E1F268AD02
P2860
When should an effective treatment be used? Derivation of the threshold number needed to treat and the minimum event rate for treatment.
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
When should an effective treat ...... imum event rate for treatment.
@ast
When should an effective treat ...... imum event rate for treatment.
@en
type
label
When should an effective treat ...... imum event rate for treatment.
@ast
When should an effective treat ...... imum event rate for treatment.
@en
prefLabel
When should an effective treat ...... imum event rate for treatment.
@ast
When should an effective treat ...... imum event rate for treatment.
@en
P2093
P1476
When should an effective treat ...... imum event rate for treatment.
@en
P2093
P304
P356
10.1016/S0895-4356(01)00347-X
P577
2001-03-01T00:00:00Z